Logo image of BOLD

BOUNDLESS BIO INC (BOLD) Stock Fundamental Analysis

NASDAQ:BOLD - Nasdaq - US10170A1007 - Common Stock - Currency: USD

1.05  -0.04 (-3.67%)

After market: 1.05 0 (0%)

Fundamental Rating

3

Taking everything into account, BOLD scores 3 out of 10 in our fundamental rating. BOLD was compared to 559 industry peers in the Biotechnology industry. BOLD has a great financial health rating, but its profitability evaluates not so good. BOLD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BOLD has reported negative net income.
BOLD had a negative operating cash flow in the past year.
BOLD Yearly Net Income VS EBIT VS OCF VS FCFBOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.35%, BOLD is in the better half of the industry, outperforming 62.25% of the companies in the same industry.
BOLD has a Return On Equity of -48.09%. This is in the better half of the industry: BOLD outperforms 66.55% of its industry peers.
Industry RankSector Rank
ROA -34.35%
ROE -48.09%
ROIC N/A
ROA(3y)-43.16%
ROA(5y)N/A
ROE(3y)-51.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BOLD Yearly ROA, ROE, ROICBOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLD Yearly Profit, Operating, Gross MarginsBOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BOLD has more shares outstanding
BOLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLD Yearly Shares OutstandingBOLD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
BOLD Yearly Total Debt VS Total AssetsBOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -1.75, we must say that BOLD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.75, BOLD is in line with its industry, outperforming 55.46% of the companies in the same industry.
There is no outstanding debt for BOLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.75
ROIC/WACCN/A
WACCN/A
BOLD Yearly LT Debt VS Equity VS FCFBOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 22.15 indicates that BOLD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 22.15, BOLD belongs to the best of the industry, outperforming 94.99% of the companies in the same industry.
A Quick Ratio of 22.15 indicates that BOLD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 22.15, BOLD belongs to the top of the industry, outperforming 94.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15
BOLD Yearly Current Assets VS Current LiabilitesBOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

BOLD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -456.85%.
EPS 1Y (TTM)-456.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.65% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.89%
EPS Next 2Y34.56%
EPS Next 3Y21.65%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BOLD Yearly EPS VS EstimatesBOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BOLD. In the last year negative earnings were reported.
Also next year BOLD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLD Price Earnings VS Forward Price EarningsBOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLD Per share dataBOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLD's earnings are expected to grow with 21.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.56%
EPS Next 3Y21.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BOLD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOUNDLESS BIO INC

NASDAQ:BOLD (6/13/2025, 8:00:02 PM)

After market: 1.05 0 (0%)

1.05

-0.04 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)N/A N/A
Inst Owners74.5%
Inst Owner Change38.52%
Ins Owners3.05%
Ins Owner Change0%
Market Cap23.51M
Analysts45.71
Price Target3.06 (191.43%)
Short Float %2.8%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.07%
Min EPS beat(2)4.85%
Max EPS beat(2)5.3%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)2.94%
Max EPS beat(4)5.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-80%
PT rev (3m)-79.31%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)1.58%
EPS NY rev (1m)0%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-2.96
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.66
OCFYN/A
SpS0
BVpS6.1
TBVpS6.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.35%
ROE -48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.16%
ROA(5y)N/A
ROE(3y)-51.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 220.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z -1.75
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-456.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.21%
EPS Next Y76.89%
EPS Next 2Y34.56%
EPS Next 3Y21.65%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.51%
EBIT Next 3Y-16.14%
EBIT Next 5YN/A
FCF growth 1Y-33.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.85%
OCF growth 3YN/A
OCF growth 5YN/A